No abstract available.
Carcinoma, Renal Cell*

No abstract available.
Carcinoma, Renal Cell*

No abstract available.

No abstract available.
Carcinoma, Renal Cell* ; Survival Rate*

No abstract available.
Laser Coagulation* ; Prostatic Hyperplasia*

Rivaroxaban is a new oral anticoagulant used for the prevention of stroke in patients with atrial fibrillation. Hemorrhagic pericarditis is known to occur with rivaroxaban; however, only a few case reports in the literature describe such events. Recently, we experienced hemorrhagic pericarditis that treated with rivaroxaban for anticoagulation of newly diagnosed, non valvular AF patients with pacemaker. An 83 year old male with permanent pacemaker receiving rivaroxaban 20 mg daily once for 3 months presented at our emergency department complaining of exertional dyspnea. ECG showed intermittent atrial pacing failure and echocardiography showed large amount of pericardial effusion. After urgent pericardiocentesis, which resulted in removal of 500cc bloody fluid, there was an immediate and dramatic improvement in the patient's clinical state. He was discharged without anticoagulation therapy due to concern for further bleeding. This case highlight the potential for bleeding complications associated with novel anticoagulants. Rivaroxaban is being used with increasing frequently in outpatient care. However, no available laboratory test specifically measures the anticoagulant effect of rivaroxaban. Also, in the events of serious bleeding, no specific antidotes, reversal agents were available. Clinicians should be aware of the possibility of hemopericardium in patients treated with anticoagulants, including rivaroxaban who presented with cardiomegaly.
Ambulatory Care ; Anticoagulants ; Antidotes ; Atrial Fibrillation* ; Cardiomegaly ; Dyspnea ; Echocardiography ; Electrocardiography ; Emergency Service, Hospital ; Hemorrhage ; Humans ; Male ; Pericardial Effusion ; Pericardiocentesis ; Pericarditis* ; Rivaroxaban* ; Stroke

The patient with metastatic renal cell carcinoma at the time of presentation have an average survival of approximately 4 months, and only 10% can be expected to survive 1 year. The treatment of metastatic renal cell carcinoma remains a major public health problem in clinical medicine. Hormonal therapies, including progestational agents, and chemotherapies as single agent or in combinations seldom result in objective tumor regression or prolongation of survival and the response are usually temporary. Immunotherapic approaches to this tumor has not demonstrated a clear impact on growth of the tumor. But alpha-interferon therapy that initiated by deKernion produced 16. 5% response rate. The following results and conclusions are obtained with combination therapy such as a-interferon. nitrosourea, vinblastine and medroxyprogesteron acetate in metastatic renal cell carcinoma. 1. From March 1988 to August 1989, 15 patients with metastatic renal cell carcinoma were studied. Average patient age was 49.3 years. There was 11 men and 4 women. The disease was confined to lung in 46.7% of the patients and a Karnofsky performance status (PS) of 100 was identified in 7%: 13.3 % had PS score <70. 2. Of 15 patients, 4(26.7%) had a complete responses, 1 (6.7%) had a partial response, 3 (20.0%) had a minimal response and 7 (46.7%) had progression with no evidence of response to treatment. Of patients with pulmonary metastases alone, 5 (71.4%) had objective response or stabilization of disease and 2 (28.6%) had progression with no evidence of response to treatment. 1 (100.0%) patient with PS of 100 had partial response and no patients with PS<70 had response to therapy. 3. Median duration of survival in the overall subjects was 47 weeks : nonresponders survived for median of 21 weeks. Median duration of survival in nonresponders with pulmonary metastasis alone was 20 weeks. All responders are alive at least 33 weeks later. 4. The most common side effects were constitutional symptoms (73.3%). Hematologic toxicity (60%), gastrointestinal toxicity (40%), hepatic toxicity (26.7%) and nephrotoxicity (6.7%) occurred. Severe toxicity was noted only in 1 patient. 5. Natural killer cell activity in responders was 35.4 % and in nonresponders was 43.0%. Increased natural killer cell in responders was noted after treatment. T Lymphocyte subletting (T3 : cytotoxic T cell, T4 : helper T cell, T8 : suppressor T cell) performed at peritreatment had no statistic significance.In spite of short-term study, combination therapies includirrg alpha-interferon cause objective more regression and prolongation of survival. Futher trial with these regimens seem warranted in the management of metastatic renal cell carcinoma.
Carcinoma, Renal Cell* ; CD8-Positive T-Lymphocytes ; Clinical Medicine ; Drug Therapy ; Female ; Humans ; Interferon-alpha* ; Karnofsky Performance Status ; Killer Cells, Natural ; Lung ; Lymphocytes ; Male ; Neoplasm Metastasis ; Progestins ; Public Health ; Vinblastine

Various clinical evaluations in urological aspects were performed on 100 renal transplantations in the Department of Urology, Kosin Medical College from December 1984 to August l988. The following results were obtained. 1. Year distributions were as follows : 1 case was done in 1984, 5 cases in 1986, 31 cases in 1986, 30 cases in 1987, 33 cases in 1988. 2. Of 100 donors 44 cases were male and 56 cases were female. Sixth decade was most common. Of 100 recipients 71 cases were male and 29 cases were female. Fourth decade was must common. 3. Of all living-related donors 89 cases were related donors and 11 cases were unrelated donors. 4. The most common underlying renal disease requiring transplantation was chronic glomerulonephritis (90%) and reflux nephropathy was 2 cases(2 %). 5. All surgical approaches of donor nephrectomy were flank incision, usually with removal of 12th rib(59%). Selected kidney side was follow : 79 cases were left side and 21 cases was right side. 6. The ureteroneocystostomy was performed with modified Politano-Leadbetter method in initial 3 cases and extravesical Mac Kinnon method in 97 cases. 7. Our incidence of urological complications in 100 renal transplantations was 8%(8 cases). 6 cases were ureteral obstructions due to perinephric hematoma, 1 case was ureterotaneous fistula and 1 cases was bladder leakage. 8. Our incidence of complications in 100 donor nephrectomy was 3%(3 cases). 1 case was pleural effusion, 1 case was atelectasis and 1 case was perforation of stomach. 9. Results and prognosis in complicated cases were good.
Female ; Fistula ; Glomerulonephritis ; Hematoma ; Humans ; Incidence ; Kidney ; Kidney Transplantation* ; Male ; Nephrectomy ; Pleural Effusion ; Prognosis ; Pulmonary Atelectasis ; Stomach ; Tissue Donors ; Unrelated Donors ; Ureteral Obstruction ; Urinary Bladder ; Urology

We evaluated the urologic complications of extravesical ureteroneocystostomy in 60 renal transplantation performed in the Department of Urology, Kosin Medical College during the period from December 1984 to August 1987. The results were as follows 1. Of 60 cases of recipient 39 cases were male and 21 cases were female. In donor and recipient`s relationship, 53 cases related and 7 cases were unrelated. 2. Our incidence of postoperative urologic complications of extravesical ureteroneocystostomy in 60 renal transplantation was 5 cases(8.3%). 3. The details of complications were as follow : 4 cases(6.7%) were ureteral obstruction due to perirenal hematoma and 1 case(1.6%) was ureteral fistula. 4. Treatment of complications were immediate perirenal hematoma removal in ureteral obstruction(4) and silastic drain in ureteral fistula(1). 5. Results and prognosis in complicated cases were good.
Female ; Fistula ; Hematoma ; Humans ; Incidence ; Kidney Transplantation* ; Male ; Prognosis ; Tissue Donors ; Ureter ; Ureteral Obstruction ; Urology

Recently, to find a change of cellular immunologic function, the development of monoclonal anti-body for surface antigen of T cell subsets is used as an important method of quantitative and functional measure in T cell subsets. We evaluated the T cell subsets in the peripheral blood of 145 normal control group and 106 bladder cancer group which was diagnosed by tissue pathology during the period from June 1986 to June 1992. The results of this study showed that CD3 of T cell subsets was significantly decreased in bladder cancer group as compared with normal control group(p<0.05) and significantly decreased in T1 and T1 groups of bladder cancer groups(p<0.05). But CD4/CD8 ratio was not decreased in bladder cancer group as compared with normal control group.
Antigens, Surface ; Humans ; Immunity, Cellular ; Pathology ; T-Lymphocyte Subsets* ; Urinary Bladder Neoplasms* ; Urinary Bladder*